Labcorp, also known as
Laboratory Corporation of America Holdings, is set to announce its Q2 2025 Earnings on July 24. The company's stock has risen by 25.6% this year due to various factors.
Morgan Stanley has affirmed an 'Overweight' rating for Labcorp and set forth a
price target of $283. Additionally, Labcorp's acquisition of the assets of
BioReference Health's Innovative Oncology and Clinical Testing Services has been announced, adding to the company's portfolio. Labcorp has incorporated a new 1000+ biomarker platform to aid holistic healthcare. Following recent earnings,
Barclays has adjusted Labcorp's price target to $275 considering the Q2 Outlook. Meanwhile, promising innovations continue to emerge from Labcorp, including a
full-scale test portfolio for faster cancer care treatment decisions and the launch of Whole Health Solutions for holistic care. Added to this, Labcorp's stock gains have also been fueled by its
acquisition of BioReference Health and the launch of private self-collection options for HPV testing. Unfortunately, the company recently faced a closure of an acquired laboratory that caused layoffs. As growth continues to increase, Labcorp maintains its place among the leaders, particularly the
S&P 500 healthcare providers, and also retains a dominant position in the diagnostic and testing services industry.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 06 Apr 2011 07:00:00 GMT to Thu, 26 Jun 2025 23:30:11 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -5
